WHY IT MATTERS: Patients who use cannabis in the evening for sleep, pain, or anxiety need accurate information about whether they are functionally safe to drive the following morning, because current legal standards often conflate cannabinoid detection with actual impairment. CLINICAL OVERVIEW: The relationship between cannabis consumption and next-day driving performance is a genuinely complex clinical and policy question, shaped by factors including frequency of use, tolerance, cannabinoid pharmacokinetics, and the wide variability in how individuals metabolize THC. Frequent cannabis users develop meaningful neuroadaptation over time, which alters both subjective intoxication and measurable psychomotor function in ways that occasional users do not experience.
West Virginia House approves bill allowing medical cannabis edibles | WV News
WHY IT MATTERS: West Virginia medical cannabis patients who previously had limited delivery options may soon be able to access edible formulations, giving physicians and patients more tools to tailor treatment to individual medical needs. CLINICAL OVERVIEW: West Virginia’s expansion of its medical cannabis program to include edible formulations represents a meaningful step toward improving patient access and treatment flexibility. Edibles offer distinct pharmacokinetic advantages for certain patient populations, particularly those with respiratory conditions who cannot tolerate inhalation, or those requiring longer-duration symptom relief due to the slower onset and extended duration of orally administered cannabinoids.
DOSE) (OTCQB: RDTCF) Advances QuickStrip™ Research Backed by NFL … – StreetInsider
WHY IT MATTERS: If thin-film CBD delivery is confirmed to offer superior and more consistent bioavailability compared to traditional oral products, patients may need to recalibrate their doses when switching formats to avoid unintended underdosing or overdosing. CLINICAL OVERVIEW: Sublingual and buccal thin-film delivery systems represent a meaningful departure from conventional oral cannabinoid formats because they bypass first-pass hepatic metabolism, potentially improving both the speed of onset and the consistency of systemic absorption. CBD delivered through mucoadhesive strip technology may achieve higher bioavailability compared to standard oil-based or capsule formulations, which are notoriously variable due to differences in fed versus fasted states and individual digestive physiology.